跳至主要内容
临床试验/NCT04289441
NCT04289441已完成不适用

"Randomized Controlled Double-blind Trial With Lactobacillus Salivarius LS01 (DSM 22775) and Bifidobacterium Breve B632 (DSM 24706) for Paediatric Asthma Management"

Probiotical S.p.A.2 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2017年4月21日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
46
试验地点
2
主要终点
Reduction in Asthma episodes

研究概览

简要总结

Randomized controlled double-blind trial in a child population with allergic asthma and recurring wheezing, undergoing probiotic treatment with Bifiasthm with the aim of assessing the reduction in asthma attacks.

详细描述

Allergic disorders have dramatically increased in prevalence over the past decade, particularly in developed countries, and primary prevention of allergic disease has proved an elusive goal. There is increasing evidence that the airway microbiome influences the development of wheezing and childhood asthma. Probiotics are increasingly considered as a promising treatment for the correction of dysbiosis, reduction of systemic inflammation, and modulation of allergic diseases. The aim of this study is, therefore, to evaluate the efficacy of Bifidobacterium breve B632 (DSM 24706) and Lactobacillus salivarius LS01 (DSM 22775) in the prevention of asthmatic allergies in human subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
1 Year 至 14 Years(Child)
性别
All
接受健康志愿者

入选标准

  • The study will include all children aged 6 to 14, with slight and moderate persistent asthma according to GINA 2015 criteria (asthma classification did not change in GINA 2015 and 2016 guidelines), whether or not showing positive skin allergometric tests, as well as all children aged 2 yrs, 364 days to 5 years, 364 days, with recurring wheezing, whether or not diagnosed with asthma (positive and/or negative prick).

排除标准

  • Severe persistent asthma
  • Known congenital or acquired immunodeficiencies
  • Cystic fibrosis
  • Chronic pulmonary diseases (bronchodysplasia)
  • Age < 1 yr, 364d and 14 yrs

结局指标

主要结局

Reduction in Asthma episodes

时间窗: 12 months

Reduction in the frequency and severity of asthma crises, the evaluation is performed using Guidelines for management of Asthma, Italian Society of Pediatricians

Reduction in wheezing

时间窗: 12 months

Reduction in the frequency of wheezing episodes, numerical evaluation.

次要结局

  • Reduction of adminstrated drug quantity(12 months)
  • Reduction in treatment time(12 months)

研究者

发起方
Probiotical S.p.A.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验